- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PEPGEN Aktie jetzt für 0€ handeln | |||||
| 06.08. | PepGen GAAP EPS of -$0.26 | 2 | Seeking Alpha | ||
| 06.08. | PepGen advances DM1 trial to highest dose cohort | 1 | Investing.com | ||
| 06.08. | PepGen Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.08. | PepGen Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 22.06. | PepGen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.06. | Craig-Hallum initiates PepGen stock coverage with buy rating | 12 | Investing.com | ||
| 21.05. | H.C. Wainwright reiterates PepGen stock rating on data outlook | 3 | Investing.com | ||
| 21.05. | PepGen Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 12.05. | PepGen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | PepGen Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 31.03. | Why Is PepGen Stock Sinking Tuesday? | 3 | Benzinga.com | ||
| 31.03. | PepGen crashes after mid-stage trial data for muscle disorder therapy | 2 | Seeking Alpha | ||
| 30.03. | PepGen-Aktie stürzt nach enttäuschenden Studiendaten um 44 % ab | 7 | Investing.com Deutsch | ||
| 30.03. | PepGen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | PepGen reports mixed results from DM1 trial, 10mg cohort ongoing | 2 | Investing.com | ||
| 05.03. | PepGen muscular dystrophy drug gets 'surprise' hold from FDA | 2 | BioPharma Dive | ||
| 05.03. | Stifel reiterates Buy on PepGen stock amid partial clinical hold | 7 | Investing.com | ||
| 05.03. | PepGen slumps as FDA places hold on lead drug | 1 | pharmaphorum | ||
| 05.03. | PepGen slides on FDA partial hold on mid-stage trial for lead asset | 1 | Seeking Alpha | ||
| 05.03. | PepGen hit with partial clinical hold, analysts blame 'understaffed FDA' | 2 | FierceBiotech |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| AMGEN | 371,90 | -0,35 % | Amgen: Tezspire Demonstrates Positive Phase 3 Results In Eosinophilic Esophagitis Across Both Co-primary And All Key Secondary Endpoints | Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52
Efficacy in a Third Epithelial-Driven... ► Artikel lesen | |
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| BIOGEN | 187,62 | -0,51 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 10,500 | +0,19 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| VIVOSIM LABS | 0,286 | +0,25 % | VivoSim Labs, Inc.: VivoSim Provides Financial and Listing Compliance Update | SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models... ► Artikel lesen | |
| OCUGEN | 1,162 | +1,57 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,228 | +2,24 % | BioNxt erreicht wichtigen Meilenstein im klinischen Cladribin-Programm für MS mit Abschluss des IMPD vor Beginn der klinischen Studien am Menschen | VANCOUVER, BC / ACCESS Newswire /
26. August 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FWB:BXT), ein innovatives
Biowissenschaftsunternehmen, das... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,070 | -3,60 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,850 | +0,36 % | Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| TEMPUS AI | 55,25 | -0,04 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? | ||
| VIVORYON THERAPEUTICS | 1,125 | -0,88 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,450 | -0,35 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 55,62 | -1,31 % | Piper Sandler reiterates Overweight on BioMarin stock at $88 target |
Das Unternehmen PEPGEN INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,080 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PEPGEN INC finden Sie auf Wallstreet Online.